AngioLab, Inc. engages in the development, manufacture, and distribution of pharmaceutical products. Its products include medicines for ophthalmic disorders, periodontal diseases, anti-obesity drugs, anti-inflammation treatments, and psoriasis cares, health functional foods for internal organ fat controls, and cosmetics for anti-wrinkle. The company was founded by Kim Min-Yeong on June 3, 1999 and is headquartered in Daejeon, South Korea.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company